Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
Completed
ZS Pharma, Inc.
Phase 3
2014-03-31
It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in
maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium
levels (3.5 - 5.0 mmol/l, inclusive) among hyperkalemic subjects in whom normokalemia was
established during the open-label acute phase versus no difference between each ZS dose
(highest to lowest) versus placebo control (null hypothesis).
Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.
Completed
ZS Pharma, Inc.
Phase 3
2014-05-31
Subjects who completed the Double-blind Randomized Maintenance Phase (DBRMP) Study Day 29
visit in ZS-004 (NCT 02088073) and have an i-STAT potassium value that is 3.5 to 6.2 mmol/l
inclusive or who discontinued during ZS-004 due to hypo- or hyperkalemia in the DBRMP and
have a mean i-STAT potassium value from two consecutive measurements at 0 and 60 minutes on
Acute Phase Day 1/Maintenance Phase Day 1 that is 3.5 to 6.2 mmol/l inclusive may have the
option to participate in ZS-004E (NCT 021070920). Subjects who discontinued from study ZS-004
due to any other reasons (e.g. adverse events, poor compliance, investigator decision) will
not be entered into study ZS-004E. All subjects who continue into the extension study must
begin dosing within two (2) days after the last dose of investigational product in ZS-004.
Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months
Completed
ZS Pharma, Inc.
Phase 3
2014-06-30
The Open-Label Maintenance Study contains an Acute Phase, in which subjects will be dosed
with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a long-term Maintenance
Phase.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
